Is Becton Dickinson and Co (BDX) a Stock to Watch After Gaining 1.00% This Week?

The market has been down on Becton Dickinson and Co (BDX) stock recently. BDX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Becton Dickinson and Co has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on BDX!

See Full BDX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BDX Stock Today?

Becton Dickinson and Co (BDX) stock has risen 0.86% while the S&P 500 has fallen -0.28% as of 2:36 PM on Tuesday, Nov 21. BDX has gained $2.01 from the previous closing price of $233.67 on volume of 889,932 shares. Over the past year the S&P 500 is up 14.81% while BDX has gained 0.42%. BDX earned $5.10 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 46.22. To screen for more stocks like Becton Dickinson and Co click here.

More About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business. Click Here to get the full Stock Report for Becton Dickinson and Co stock.